ライフサイエンスコーパス: severe combined immunodeficiency

1 kidney capsules of SCID mice (ie, mice with severe combined immunodeficiency).

2 ally attenuated MM tumor growth in mice with severe combined immunodeficiency.

3 benefits with gene therapy for ADA-deficient severe combined immunodeficiency.

4 ng Tgfb1-null mutant mice on a background of severe combined immunodeficiency.

5 in Matrigel, and formed tumors in mice with severe combined immunodeficiency.

6 ratoma assays in nonobese diabetic mice with severe combined immunodeficiency.

7 c), which is mutated in humans with X-linked severe combined immunodeficiency.

8 ion and subsequently received a diagnosis of severe combined immunodeficiency.

9 logical process defective in human and mouse severe combined immunodeficiency.

10 Amish infant hospitalized in Minnesota with severe combined immunodeficiency.

11 reased sensitivity to ionizing radiation and severe combined immunodeficiency.

12 ression is defective in humans with X-linked severe combined immunodeficiency.

13 ntified in patients with NHEJ deficiency and severe combined immunodeficiency.

14 ngs with T cell, B cell, natural killer cell severe combined immunodeficiency.

15 d kinase, Jak3, are the major cause of human severe combined immunodeficiency.

16 ients display radiosensitivity combined with severe combined immunodeficiency.

17 in humans and null mutations in mice lead to severe combined immunodeficiency.

18 ly, such protection occurred without causing severe combined immunodeficiency.

19 inactivated in human radiosensitive T(-)B(-) severe combined immunodeficiency, a syndrome characteriz

20 affected with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out

21 c contrast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients hav

22 'difficult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histo

23 ites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often refer

24 clude adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-B

25 s a disorder of purine metabolism leading to severe combined immunodeficiency (ADA-SCID).

26 clinical case of an RSV-infected infant with severe combined immunodeficiency and effectively no adap

27 These features are consistent with the severe combined immunodeficiency and mild extraimmunolog

28 Mutations associated with severe combined immunodeficiency and Omenn syndrome had

29 g its goal of defining the true incidence of severe combined immunodeficiency and providing early tre

30 primary immunodeficiencies (PIDs) including severe combined immunodeficiency and Wiskott-Aldrich syn

31 ells injected intraperitoneally (ie, in CB17 severe combined immunodeficiencies) and significantly in

32 , diagnosis of adenosine deaminase-deficient severe combined immunodeficiency, and consanguinity were

33 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimm

34 g in California established the incidence of severe combined immunodeficiency at 1 in 66,250 live bir

35 ons in Orai1 Ca2+ channels lead to a form of severe combined immunodeficiency, auto-immunity, muscle

36 ype per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

37 ) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 9

38 C.B.-17 severe combined immunodeficiency-beige mice were transpl

39 yptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the par

40 raftment is a common finding in infants with severe combined immunodeficiency but is not typically ob

41 ions in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 d

42 ete recovery occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type m

43 correct T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident t

44 delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in

45 eficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of

46 Severe combined immunodeficiency can be caused by loss-o

47 ells has emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutatio

48 chain cytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack o

49 Norovirus incidence was compared between severe combined immunodeficiency children with (n = 10)

50 orrection of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous

51 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knoc

52 was unequivocal evidence that children with severe combined immunodeficiency could be cured by gene

53 Newborn screening for severe combined immunodeficiency detects athymic patient

54 marked decrease in survival and developed a severe combined immunodeficiency disease (SCID) affectin

55 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and rela

56 BHK tumors growing as xenografts in severe combined immunodeficiency disease (SCID) mice wer

57 n of EBV-CTLs both in vitro and in vivo in a severe combined immunodeficiency disease (SCID) mouse mo

58 wn to lead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

59 the gene encoding CRACM1 is associated with severe combined immunodeficiency disease in humans.

60 s, whereas transfers into BALB/c x Rag-/- or severe combined immunodeficiency disease mice (H-2d) did

61 ligoclonal lines into either C3H x Rag-/- or severe combined immunodeficiency disease mice (H-2k) als

62 PET experiments were performed in severe combined immunodeficiency disease mice inoculated

63 Patients with severe combined immunodeficiency disease who have matche

64 12 was found to be mutated in patients with severe combined immunodeficiency disease, and expression

65 d adults with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

66 ications of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by

67 r from healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, follo

68 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were i

69 y CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under

70 and patients with atypical presentations of severe combined immunodeficiency gene mutations presents

71 treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improv

72 patients with adenosine deaminase deficient severe combined immunodeficiency have identified neutrop

73 HTLV-1-infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were

74 th and prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

75 Last, treatment of severe combined immunodeficiency-human (SCID-hu) mice wi

76 gnificantly inhibited C4-2B cell growth in a severe combined immunodeficiency-human model of experime

77 Although its complete defect causes severe combined immunodeficiency (ie, T(-)B(-) severe co

78 homing, and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) m

79 In 6.5 years of newborn screening for severe combined immunodeficiency in California, 3,252,15

80 HEJ factor ARTEMIS cause radiation-sensitive severe combined immunodeficiency in humans and may incre

81 e gene encoding gamma(c) results in X-linked severe combined immunodeficiency in humans, and gamma(c)

82 geneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(nul

83 nstitute immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac re

84 Therefore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

85 stitution by transplanting nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

86 vere combined immunodeficiency (ie, T(-)B(-) severe combined immunodeficiency), its suboptimal activi

87 gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Ama

88 oss of T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome

89 ndent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

90 lial cells, leading to increased survival of severe combined immunodeficiency mice after transplantat

91 (+) fetal liver cells into nonobese diabetic/severe combined immunodeficiency mice allows for the lon

92 n vivo after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated

93 umab and copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xe

94 In female CB17 severe combined immunodeficiency mice bearing Colo205 xe

95 ession by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumo

96 in vivo experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenogr

97 ol Tyr(4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenog

98 d not reduce infectivity or pathogenicity in severe combined immunodeficiency mice but resulted in cl

99 of human erythrocytes into nonobese diabetic/severe combined immunodeficiency mice extends blood circ

100 LL cells transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapit

101 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive be

102 omib significantly prolonged the survival of severe combined immunodeficiency mice inoculated with LC

103 myofibers in the injured skeletal muscle of severe combined immunodeficiency mice more effectively t

104 Six nonobese diabetic severe combined immunodeficiency mice received transplan

105 uppressed the development of diabetes in NOD severe combined immunodeficiency mice receiving diabetog

106 tumor transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knoc

107 plantation in xenotolerant nonobese diabetic/severe combined immunodeficiency mice through intrasplen

108 ansplanted nonobese diabetic background with severe combined immunodeficiency mice to assess suppress

109 Nonobese diabetic/severe combined immunodeficiency mice transplanted with

110 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a

111 Male severe combined immunodeficiency mice were subcutaneousl

112 Humanized urokinase plasminogen activator/severe combined immunodeficiency mice were used to estab

113 transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significant

114 antly improved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemi

115 ease severity during persistent infection of severe combined immunodeficiency mice with isogenic sero

116 nd decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with P

117 EB-silenced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth

118 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also ef

119 MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the im

120 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of hu

121 esis in immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an onc

122 o a different genogroup, are inoculated into severe combined immunodeficiency mice, the order of seve

123 E. chaffeensis strains were inoculated into severe combined immunodeficiency mice, the order of the

124 ng MDA-MB-231 cell-derived mammary tumors in severe combined immunodeficiency mice, we show here for

125 ibroblasts and in aggressive tumor growth in severe combined immunodeficiency mice.

126 antly inhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

127 in vitro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

128 ted in the choroids of six nude rats and six severe combined immunodeficiency mice.

129 otype when transplanted to nonobese diabetic/severe combined immunodeficiency mice.

130 tive transfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

131 presses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

132 in human PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

133 d into the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

134 g soft agar assays and xenograft analysis of severe combined immunodeficiency mice.

135 x vivo leukemic cells into nonobese diabetic/severe combined immunodeficiency mice.

136 al cavity of streptozotocin-induced diabetic severe combined immunodeficiency mice.

137 ells are tumorigenic in both male and female severe combined immunodeficiency mice.

138 ive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

139 ing CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

140 ro, and suppressed tumor xenograft growth in severe combined immunodeficiency mice.

141 lanted subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

142 he same day prior to graft implantation into severe combined immunodeficiency mice.

143 ppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

144 sis utilizing a human CaP xenograft model in severe-combined immunodeficiency mice.

145 SCID (severe combined immunodeficiency) mice underwent left an

146 tudies were performed in Mec-1-bearing SCID (severe combined immunodeficiency) mice, a new animal mod

147 When xenografted into SCID (severe combined immunodeficiency) mice, the expression o

148 s been found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.

149 medulloblastomas in an orthotopic, xenogenic severe combined immunodeficiency model.

150 In human artery-severe combined immunodeficiency mouse chimeras, in whic

151 nsplantation into diabetic nonobese diabetic-severe combined immunodeficiency mouse kidneys.

152 nd virulence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

153 tensively in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV path

154 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those anti

155 assayable human cells, the nonobese diabetic/severe combined immunodeficiency mouse repopulating cell

156 d engraftment in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mouse myocardium incre

157 tem with experimental systemic infections of severe combined immunodeficiency Mus musculus with the b

158 tuted with a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

159 under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MS

160 l CD34(+) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulte

161 Here, we show that nonobese diabetic severe combined immunodeficiency (NOD/SCID) beta(2) micr

162 aclizumab was evaluated in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice given i

163 cells into immunodeficient nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice leads t

164 th allogeneic T cells into nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice resulte

165 A-overexpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with pa

166 rs when transplanted into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice.

167 (STZ)-induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

168 and after engraftment in a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenogr

169 hat when transplanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) recipient mi

170 and nail dystrophy, accounting for the nude/severe combined immunodeficiency (nu/SCID) phenotype in

171 ere divided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and co

172 ency causes T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia w

173 mmune system since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mic

174 ce represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest t

175 emis nuclease is defective in radiosensitive severe combined immunodeficiency patients and is require

176 h overexpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-defic

177 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T

178 A 14-year-old boy with severe combined immunodeficiency presented three times t

179 ons are responsible for the development of a severe combined immunodeficiency [radiation-sensitive (R

180 rchy contains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

181 telangiectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively

182 function therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

183 - and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from dissemin

184 A subgroup of severe combined immunodeficiencies (SCID) is characteriz

185 fection, wild-type (WT) and C3H animals with severe combined immunodeficiency (SCID animals) were ino

186 success in select diseases such as X-linked severe combined immunodeficiency (SCID) and ADA deficien

187 function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many

188 n the brain, brain stem, and spinal cords of severe combined immunodeficiency (SCID) and C57BL/6 (wil

189 with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular rad

190 alues and severely impaired dissemination in severe combined immunodeficiency (SCID) and immunocompet

191 oietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primar

192 Population-based newborn screening for severe combined immunodeficiency (SCID) and related diso

193 Severe combined immunodeficiency (SCID) and X-linked aga

194 Severe combined immunodeficiency (SCID) arises from diff

195 Severe combined immunodeficiency (SCID) can be cured by

196 018), we show that over 90% of patients with severe combined immunodeficiency (SCID) can be genetical

197 Severe combined immunodeficiency (SCID) carries a poor p

198 tivating gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a comp

199 Severe combined immunodeficiency (SCID) comprises a grou

200 Severe combined immunodeficiency (SCID) comprises a hete

201 to the pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been pre

202 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide

203 in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

204 Severe combined immunodeficiency (SCID) is a life-threat

205 Early recognition of severe combined immunodeficiency (SCID) is a pediatric e

206 Severe combined immunodeficiency (SCID) is a syndrome of

207 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by gen

208 Severe combined immunodeficiency (SCID) is characterized

209 Severe combined immunodeficiency (SCID) is characterized

210 adenosine deaminase (ADA) cause a subtype of severe combined immunodeficiency (SCID) known as severe

211 MA I&T was determined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mice after sacri

212 s of galectin-1 were higher in tumor-bearing severe combined immunodeficiency (SCID) mice breathing 1

213 verexpressing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

214 th in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice.

215 ls within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice.

216 ed p44E was used to infect a naive horse and severe combined immunodeficiency (SCID) mice.

217 tiated by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

218 In human artery-severe combined immunodeficiency (SCID) mouse chimeras,

219 udies using a CD4+CD45Rbhigh T-cell transfer severe combined immunodeficiency (SCID) mouse inflammato

220 ignificant prolonged survival in a xenograft severe combined immunodeficiency (SCID) mouse model of d

221 ed autophagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of V

222 wth of RARalpha2-overexpressing MM tumors in severe combined immunodeficiency (SCID) mouse model.

223 me for at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft

224 se of nonobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID)

225 fetal liver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gamm

226 ic and nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with ei

227 histone H3 recognition were found mutated in severe combined immunodeficiency (SCID) patients.

228 Severe combined immunodeficiency (SCID) represents conge

229 Severe combined immunodeficiency (SCID) represents the m

230 Although gene therapy can cure patients with severe combined immunodeficiency (SCID) syndromes, the c

231 dysgenesis is an autosomal recessive form of severe combined immunodeficiency (SCID) that usually man

232 onsortium (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective

233 Newborn screening for severe combined immunodeficiency (SCID) using assays to

234 We report here a patient with T(-)B(+)NK(+) severe combined immunodeficiency (SCID) who was homozygo

235 Severe combined immunodeficiency (SCID) with a complete

236 ations that impair Rag2 function can lead to severe combined immunodeficiency (SCID), a condition cha

237 the 91 position found in some patients with severe combined immunodeficiency (SCID), and the double

238 d T-cell reconstitution in many infants with severe combined immunodeficiency (SCID), but correction

239 have been identified, often associated with severe combined immunodeficiency (SCID), consistent with

240 used into young horses (foals) affected with severe combined immunodeficiency (SCID), followed by cha

241 of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefu

242 the cervical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripote

243 cell transplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survi

244 hly relevant per se because in patients with severe combined immunodeficiency (SCID), infections caus

245 minase (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in po

246 t profound primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in inf

247 The most severe form, severe combined immunodeficiency (SCID), presents with p

248 the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich

249 abrogate lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations c

250 In a severe combined immunodeficiency (SCID)-hu murine model

251 suppressed the growth of MM in vivo using a severe combined immunodeficiency (SCID)-hu murine model.

252 tations in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

253 nt of Babesia microti infection in mice with severe combined immunodeficiency (SCID).

254 ion (DRG) xenografts maintained in mice with severe combined immunodeficiency (SCID).

255 population-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

256 (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

257 recombination, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

258 g immune plasma in young horses (foals) with severe combined immunodeficiency (SCID).

259 in a significant proportion of patients with severe combined immunodeficiency (SCID).

260 cell transplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

261 erleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

262 systemic metabolic disease characterized by severe combined immunodeficiency (SCID).

263 scribe the generation of a marmoset model of severe combined immunodeficiency (SCID).

264 e T- or B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

265 ls (1 Arabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

266 T-cell development, clinically presenting as severe combined immunodeficiency (SCID).

267 repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

268 sies were injected intravenously into C.B-17 severe combined immunodeficiency (SCID)/beige (bg) mice.

269 cured immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine d

270 X-linked severe combined immunodeficiency (SCID-X1) caused by mut

271 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic

272 ietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails t

273 ical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney mu

274 fective vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have eval

275 ble for use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).

276 vector for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

277 m healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

278 X-linked severe-combined immunodeficiency (SCID-X1) has been trea

279 sseminating infections in wild-type (WT) and severe-combined-immunodeficiency (SCID) mice was analyze

280 growth in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr))

281 ell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block

282 Thus, deficiency of Stat5 results in severe combined immunodeficiency, similar in many respec

283 ations that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated wit

284 chronic inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

285 established tumors (ie, in nonobese diabetic-severe combined immunodeficiencies) that were derived fr

286 , with a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation

287 We performed a multicenter survey of severe combined immunodeficiency transplantation centers

288 Recipient mice with severe-combined immunodeficiency underwent retrorsine tr

289 nts with adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly differ

290 root ganglion (DRG) xenografts in mice with severe combined immunodeficiency using multiscale correl

291 ere identified through newborn screening for severe combined immunodeficiency using the T-cell recept

292 is with neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied b

293 natural killer cell-sufficient patient with severe combined immunodeficiency, whom we found had muta

294 ariants in AK2 cause reticular dysgenesis, a severe combined immunodeficiency with agranulocytosis, l

295 ndergone bone marrow transplant for X-linked severe combined immunodeficiency, with no recovery of T

296 r insertion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted s

297 X-linked severe combined immunodeficiency (X-SCID) is an immune d

298 liferative disease in three individuals with severe combined immunodeficiency-X1.

299 an restore immunity to infants with X-linked severe combined immunodeficiency (XSCID) caused by mutat

300 Canine X-linked severe combined immunodeficiency (XSCID) is due to mutat